{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:19:24Z","timestamp":1790194764518,"version":"4.1.0"},"publisher-location":"Cham","reference-count":108,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783031118012","type":"print"},{"value":"9783031118029","type":"electronic"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/7854_2022_330","type":"book-chapter","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T12:03:38Z","timestamp":1651665818000},"page":"19-50","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Current Pharmacological Treatments for ADHD"],"prefix":"10.1007","author":[{"given":"Madeleine J.","family":"Groom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuele","family":"Cortese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,30]]},"reference":[{"issue":"4","key":"330_CR1","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1586\/17512433.2015.1050379","volume":"8","author":"N Adamo","year":"2015","unstructured":"Adamo N, Seth S, Coghill D (2015) Pharmacological treatment of attention-deficit\/hyperactivity disorder: assessing outcomes. Expert Rev Clin Pharmacol 8(4):383\u2013397. https:\/\/doi.org\/10.1586\/17512433.2015.1050379","journal-title":"Expert Rev Clin Pharmacol"},{"key":"330_CR2","unstructured":"ADHD Institute (2021) ADHD guidelines \u2013 ADHD Institute.com. In: ADHD Institute. https:\/\/adhd-institute.com\/disease-management\/guidelines\/. Accessed 9 Jul 2021"},{"key":"330_CR3","doi-asserted-by":"publisher","DOI":"10.46995\/gpc_574","volume-title":"Gu\u00eda de Pr\u00e1ctica Cl\u00ednica sobre las intervenciones terap\u00e9uticas en el Trastorno por D\u00e9ficit de Atenci\u00f3n con Hiperactividad (TDAH)","author":"JA Alda","year":"2017","unstructured":"Alda JA, Cardo ME, D\u00edaz del Campo P, Garc\u00eda A, Gurrea A, Izaguirre J (2017) Gu\u00eda de Pr\u00e1ctica Cl\u00ednica sobre las intervenciones terap\u00e9uticas en el Trastorno por D\u00e9ficit de Atenci\u00f3n con Hiperactividad (TDAH), 1st edn Gu\u00edaSalud","edition":"1"},{"issue":"5","key":"330_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11920-019-1020-5","volume":"21","author":"KM Antshel","year":"2019","unstructured":"Antshel KM, Russo N (2019) Autism spectrum disorders and ADHD: overlapping phenomenology, diagnostic issues, and treatment considerations. Curr Psychiatry Rep 21(5):34. https:\/\/doi.org\/10.1007\/s11920-019-1020-5","journal-title":"Curr Psychiatry Rep"},{"key":"330_CR5","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, (AWMF) [Association of the Scientific Medical Societies in Germany] (2017) Long version of the interdisciplinary, evidence- and consensus-based (S3) guidelines \u201cAttention Deficit Hyperactivity Disorder (ADHD) in children, adolescents and adults\u201d (AWMF-Regiisternummmer 028-045). https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/028-045l_S3_ADHS_2018-06.pdf"},{"key":"330_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2165\/00023210-200923000-00005","volume":"23","author":"AFT Arnsten","year":"2009","unstructured":"Arnsten AFT (2009) Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology an important role for prefrontal cortex dysfunction. CNS Drugs 23:33\u201341","journal-title":"CNS Drugs"},{"key":"330_CR7","doi-asserted-by":"publisher","first-page":"107327","DOI":"10.1016\/j.nlm.2020.107327","volume":"176","author":"AFT Arnsten","year":"2020","unstructured":"Arnsten AFT (2020) Guanfacine\u2019s mechanism of action in treating prefrontal cortical disorders: successful translation across species. Neurobiol Learn Mem 176:107327. https:\/\/doi.org\/10.1016\/j.nlm.2020.107327","journal-title":"Neurobiol Learn Mem"},{"issue":"1","key":"330_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1744-9081-1-2","volume":"1","author":"AF Arnsten","year":"2005","unstructured":"Arnsten AF, Dudley AG (2005) Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: relevance to therapeutic effects in attention deficit hyperactivity disorder. Behav Brain Funct 1(1):2","journal-title":"Behav Brain Funct"},{"key":"330_CR9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1146\/annurev.neuro.28.061604.135709","volume":"28","author":"G Aston-Jones","year":"2005","unstructured":"Aston-Jones G, Cohen JD (2005) An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. Annu Rev Neurosci 28:403\u2013450. https:\/\/doi.org\/10.1146\/annurev.neuro.28.061604.135709","journal-title":"Annu Rev Neurosci"},{"key":"330_CR10","unstructured":"Australian Government National Health and Medical Research Council (2012) Clinical Practice Points \u2013 ADHD in children and adolescents | NHMRC. https:\/\/www.nhmrc.gov.au\/about-us\/publications\/clinical-practice-points-adhd-children-and-adolescents. Accessed 9 Jul 2021"},{"issue":"Suppl 1","key":"330_CR11","doi-asserted-by":"publisher","first-page":"i26","DOI":"10.1136\/adc.2004.059386","volume":"90","author":"J Barton","year":"2005","unstructured":"Barton J (2005) Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit\/hyperactivity disorder. Arch Dis Child 90(Suppl 1):i26\u2013i29. https:\/\/doi.org\/10.1136\/adc.2004.059386","journal-title":"Arch Dis Child"},{"issue":"1","key":"330_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13034-020-00351-5","volume":"15","author":"FA Bashiri","year":"2021","unstructured":"Bashiri FA, Albatti TH, Hamad MH, Al-Joudi HF, Daghash HF, Al-Salehi SM, Varnham JL, Alhaidar F, Almodayfer O, Alhossein A, Aldhalaan H, Ad-Dab\u2019bagh YA, Al Backer N, Altwaijri W, Alburikan K, Buraik MW, Ghaziuddin M, Nester MJ, Wahabi HA, Alhabib S, Jamal AA, Amer YS (2021) Adapting evidence-based clinical practice guidelines for people with attention deficit hyperactivity disorder in Saudi Arabia: process and outputs of a national initiative. Child Adolesc Psychiatry Ment Health 15(1):6. https:\/\/doi.org\/10.1186\/s13034-020-00351-5","journal-title":"Child Adolesc Psychiatry Ment Health"},{"issue":"3","key":"330_CR13","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1192\/apt.bp.108.005561","volume":"15","author":"G Bates","year":"2009","unstructured":"Bates G (2009) Drug treatments for attention-deficit hyperactivity disorder in young people. Adv Psychiatr Treat 15(3):162\u2013171. https:\/\/doi.org\/10.1192\/apt.bp.108.005561","journal-title":"Adv Psychiatr Treat"},{"key":"330_CR14","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.neubiorev.2019.11.001","volume":"108","author":"A Bellato","year":"2020","unstructured":"Bellato A, Arora I, Hollis C, Groom MJ (2020) Is autonomic nervous system function atypical in attention deficit hyperactivity disorder (ADHD)? A systematic review of the evidence. Neurosci Biobehav Rev 108:182\u2013206. https:\/\/doi.org\/10.1016\/j.neubiorev.2019.11.001","journal-title":"Neurosci Biobehav Rev"},{"issue":"3","key":"330_CR15","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1177\/1087054720972793","volume":"26","author":"A Bellato","year":"2021","unstructured":"Bellato A, Arora I, Kochhar P, Hollis C, Groom MJ (2021) Indices of heart rate variability and performance during a response-conflict task are differently associated with ADHD and autism. J Atten Disord 26(3):434\u2013446. https:\/\/doi.org\/10.1177\/1087054720972793","journal-title":"J Atten Disord"},{"issue":"9","key":"330_CR16","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1016\/j.neubiorev.2012.11.005","volume":"37","author":"CW Berridge","year":"2013","unstructured":"Berridge CW, Arnsten AFT (2013) Psychostimulants and motivated behavior: arousal and cognition. Neurosci Biobehav Rev 37(9):1976\u20131984. https:\/\/doi.org\/10.1016\/j.neubiorev.2012.11.005","journal-title":"Neurosci Biobehav Rev"},{"key":"330_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jpsychires.2020.01.006","volume":"123","author":"H Boland","year":"2020","unstructured":"Boland H, DiSalvo M, Fried R, Woodworth KY, Wilens T, Faraone SV, Biederman J (2020) A literature review and meta-analysis on the effects of ADHD medications on functional outcomes. J Psychiatr Res 123:21\u201330. https:\/\/doi.org\/10.1016\/j.jpsychires.2020.01.006","journal-title":"J Psychiatr Res"},{"issue":"2\u20133","key":"330_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0301-0511(99)00040-X","volume":"51","author":"N Borger","year":"2000","unstructured":"Borger N, van der Meere J (2000) Motor control and state regulation in children with ADHD: a cardiac response study. Biol Psychol 51(2\u20133):247\u2013267","journal-title":"Biol Psychol"},{"issue":"7","key":"330_CR19","doi-asserted-by":"publisher","first-page":"977","DOI":"10.4088\/JCP.11m07430","volume":"73","author":"M Brams","year":"2012","unstructured":"Brams M, Weisler R, Findling RL, Gasior M, Hamdani M, Ferreira-Cornwell MC, Squires L (2012) Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit\/hyperactivity disorder: randomized withdrawal design. J Clin Psychiatry 73(7):977\u2013983. https:\/\/doi.org\/10.4088\/JCP.11m07430","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"330_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.21037\/tp.2017.08.02","volume":"7","author":"KA Brown","year":"2018","unstructured":"Brown KA, Samuel S, Patel DR (2018) Pharmacologic management of attention deficit hyperactivity disorder in children and adolescents: a review for practitioners. Transl Pediatr 7(1):36\u201347. https:\/\/doi.org\/10.21037\/tp.2017.08.02","journal-title":"Transl Pediatr"},{"issue":"5","key":"330_CR21","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.biopsych.2006.03.066","volume":"61","author":"JK Buitelaar","year":"2007","unstructured":"Buitelaar JK, Michelson D, Danckaerts M, Gillberg C, Spencer TJ, Zuddas A, Faries DE, Zhang S, Biederman J (2007) A randomized, double-blind study of continuation treatment for attention-deficit\/hyperactivity disorder after 1 year. Biol Psychiatry 61(5):694\u2013699. https:\/\/doi.org\/10.1016\/j.biopsych.2006.03.066","journal-title":"Biol Psychiatry"},{"issue":"10","key":"330_CR22","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.euroneuro.2015.06.003","volume":"25","author":"J Buitelaar","year":"2015","unstructured":"Buitelaar J, Asherson P, Soutullo C, Colla M, Adams DH, Tanaka Y, Haynes VS, Escobar R, Upadhyaya H (2015) Differences in maintenance of response upon discontinuation across medication treatments in attention-deficit\/hyperactivity disorder. Eur Neuropsychopharmacol 25(10):1611\u20131621. https:\/\/doi.org\/10.1016\/j.euroneuro.2015.06.003","journal-title":"Eur Neuropsychopharmacol"},{"key":"330_CR23","volume-title":"Canadian ADHD guidelines","author":"Canadian ADHD Resource Alliance","year":"2018","unstructured":"Canadian ADHD Resource Alliance (2018) Canadian ADHD guidelines, 4th edn https:\/\/www.caddra.ca\/wp-content\/uploads\/CADDRA-Guidelines-4th-Edition_-Feb2018.pdf","edition":"4"},{"key":"330_CR24","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.neubiorev.2020.09.031","volume":"120","author":"S Carucci","year":"2021","unstructured":"Carucci S, Balia C, Gagliano A, Lampis A, Buitelaar JK, Danckaerts M, Dittmann RW, Garas P, Hollis C, Inglis S, Konrad K, Kovshoff H, Liddle EB, McCarthy S, Nagy P, Panei P, Romaniello R, Usala T, Wong ICK, Banaschewski T, Sonuga-Barke E, Coghill D, Zuddas A, ADDUCE Consortium (2021) Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysis. Neurosci Biobehav Rev 120:509\u2013525. https:\/\/doi.org\/10.1016\/j.neubiorev.2020.09.031","journal-title":"Neurosci Biobehav Rev"},{"key":"330_CR25","unstructured":"CHADD (2021) CHADD \u2013 improving the lives of people affected by ADHD. In: CHADD. https:\/\/chadd.org\/wp-content\/uploads\/2020\/02\/ADHD-Medications-Approved-by-US-FDA.pdf\/. Accessed 15 Jul 2021"},{"key":"330_CR26","doi-asserted-by":"publisher","unstructured":"Chandler DJ, Waterhouse BD, Gao W-J (2014) New perspectives on catecholaminergic regulation of executive circuits: evidence for independent modulation of prefrontal functions by midbrain dopaminergic and noradrenergic neurons. Front Neural Circuits 8. https:\/\/doi.org\/10.3389\/fncir.2014.00053","DOI":"10.3389\/fncir.2014.00053"},{"issue":"5","key":"330_CR27","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.biopsych.2019.04.009","volume":"86","author":"Z Chang","year":"2019","unstructured":"Chang Z, Ghirardi L, Quinn PD, Asherson P, D\u2019Onofrio BM, Larsson H (2019) Risks and benefits of ADHD medication on behavioral and neuropsychiatric outcomes: a qualitative review of pharmacoepidemiology studies using linked prescription databases. Biol Psychiatry 86(5):335. https:\/\/doi.org\/10.1016\/j.biopsych.2019.04.009","journal-title":"Biol Psychiatry"},{"issue":"11","key":"330_CR28","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1080\/17425255.2019.1675636","volume":"15","author":"AC Childress","year":"2019","unstructured":"Childress AC, Komolova M, Sallee FR (2019) An update on the pharmacokinetic considerations in the treatment of ADHD with long-acting methylphenidate and amphetamine formulations. Expert Opin Drug Metab Toxicol 15(11):937\u2013974. https:\/\/doi.org\/10.1080\/17425255.2019.1675636","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"12","key":"330_CR29","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1177\/0269881115602489","volume":"29","author":"DB Clemow","year":"2015","unstructured":"Clemow DB, Bushe CJ (2015) Atomoxetine in patients with ADHD: a clinical and pharmacological review of the onset, trajectory, duration of response and implications for patients. J Psychopharmacol 29(12):1221\u20131230. https:\/\/doi.org\/10.1177\/0269881115602489","journal-title":"J Psychopharmacol"},{"key":"330_CR30","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2147\/NDT.S115707","volume":"13","author":"DB Clemow","year":"2017","unstructured":"Clemow DB, Bushe C, Mancini M, Ossipov MH, Upadhyaya H (2017) A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities. Neuropsychiatr Dis Treat 13:357\u2013371. https:\/\/doi.org\/10.2147\/NDT.S115707","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"330_CR31","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/1471-244X-13-237","volume":"13","author":"D Coghill","year":"2013","unstructured":"Coghill D, Banaschewski T, Zuddas A, Pelaz A, Gagliano A, Doepfner M (2013) Long-acting methylphenidate formulations in the treatment of attention-deficit\/hyperactivity disorder: a systematic review of head-to-head studies. BMC Psychiatry 13(1):237. https:\/\/doi.org\/10.1186\/1471-244X-13-237","journal-title":"BMC Psychiatry"},{"issue":"6","key":"330_CR32","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.jaac.2014.01.017","volume":"53","author":"DR Coghill","year":"2014","unstructured":"Coghill DR, Banaschewski T, Lecendreux M, Johnson M, Zuddas A, Anderson CS, Civil R, Dauphin M, Higgins N, Lyne A, Gasior M, Squires LA (2014) Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit\/hyperactivity disorder: randomized-withdrawal study design. J Am Acad Child Adolesc Psychiatry 53(6):647\u2013657.e1. https:\/\/doi.org\/10.1016\/j.jaac.2014.01.017","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"11","key":"330_CR33","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s00787-017-0986-y","volume":"26","author":"DR Coghill","year":"2017","unstructured":"Coghill DR, Banaschewski T, Soutullo C, Cottingham MG, Zuddas A (2017) Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit\/hyperactivity disorder. Eur Child Adolesc Psych 26(11):1283\u20131307. https:\/\/doi.org\/10.1007\/s00787-017-0986-y","journal-title":"Eur Child Adolesc Psych"},{"issue":"5","key":"330_CR34","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1177\/2168479015599811","volume":"49","author":"J Connolly","year":"2015","unstructured":"Connolly J, Glessner J, Elia J, Hakonarson H (2015) ADHD & pharmacotherapy: past, present and future. Ther Innov Regul Sci 49(5):632\u2013642. https:\/\/doi.org\/10.1177\/2168479015599811","journal-title":"Ther Innov Regul Sci"},{"issue":"11","key":"330_CR35","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1056\/NEJMra1917069","volume":"383","author":"S Cortese","year":"2020","unstructured":"Cortese S (2020) Pharmacologic treatment of attention deficit-hyperactivity disorder. N Engl J Med 383(11):1050\u20131056. https:\/\/doi.org\/10.1056\/NEJMra1917069","journal-title":"N Engl J Med"},{"key":"330_CR36","doi-asserted-by":"publisher","unstructured":"Cortese S, Castellanos FX (2012) Neuroimaging of attention-deficit\/hyperactivity disorder: current neuroscience-informed perspectives for clinicians. Curr Psychiatry Rep (5):14. https:\/\/doi.org\/10.1007\/s11920-012-0310-y","DOI":"10.1007\/s11920-012-0310-y"},{"issue":"3","key":"330_CR37","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/jcpp.12036","volume":"54","author":"S Cortese","year":"2013","unstructured":"Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Graham J, Taylor E, Sergeant J (2013) Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry 54(3):227\u2013246. https:\/\/doi.org\/10.1111\/jcpp.12036","journal-title":"J Child Psychol Psychiatry"},{"issue":"9","key":"330_CR38","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","volume":"5","author":"S Cortese","year":"2018","unstructured":"Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, Atkinson LZ, Tessari L, Banaschewski T, Coghill D, Hollis C, Simonoff E, Zuddas A, Barbui C, Purgato M, Steinhausen H-C, Shokraneh F, Xia J, Cipriani A (2018) Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 5(9):727\u2013738. https:\/\/doi.org\/10.1016\/S2215-0366(18)30269-4","journal-title":"Lancet Psychiatry"},{"issue":"9","key":"330_CR39","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1002\/pds.3473","volume":"22","author":"R Cunill","year":"2013","unstructured":"Cunill R, Castells X, Tobias A, Capell\u00e0 D (2013) Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression. Pharmacoepidemiol Drug Saf 22(9):961\u2013969. https:\/\/doi.org\/10.1002\/pds.3473","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"330_CR40","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.eurpsy.2019.06.011","volume":"61","author":"D Daley","year":"2019","unstructured":"Daley D, Jacobsen RH, Lange A-M, S\u00f8rensen A, Walldorf J (2019) The economic burden of adult attention deficit hyperactivity disorder: a sibling comparison cost analysis. Eur Psychiatry 61:41\u201348. https:\/\/doi.org\/10.1016\/j.eurpsy.2019.06.011","journal-title":"Eur Psychiatry"},{"issue":"3","key":"330_CR41","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s13311-012-0126-9","volume":"9","author":"NO Davis","year":"2012","unstructured":"Davis NO, Kollins SH (2012) Treatment for co-occurring attention deficit\/hyperactivity disorder and autism spectrum disorder. Neurotherapeutics 9(3):518\u2013530. https:\/\/doi.org\/10.1007\/s13311-012-0126-9","journal-title":"Neurotherapeutics"},{"issue":"9196","key":"330_CR42","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1016\/S0140-6736(99)04030-1","volume":"354","author":"DD Dougherty","year":"1999","unstructured":"Dougherty DD, Bonab AA, Spencer TJ, Rauch SL, Madras BK, Fischman AJ (1999) Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 354(9196):2132\u20132133. https:\/\/doi.org\/10.1016\/S0140-6736(99)04030-1","journal-title":"Lancet"},{"issue":"10","key":"330_CR43","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0166-2236(00)01633-7","volume":"23","author":"J Duncan","year":"2000","unstructured":"Duncan J, Owen AM (2000) Common regions of the human frontal lobe recruited by diverse cognitive demands. Trends Neurosci 23(10):475\u2013483. https:\/\/doi.org\/10.1016\/S0166-2236(00)01633-7","journal-title":"Trends Neurosci"},{"key":"330_CR44","doi-asserted-by":"publisher","unstructured":"Epstein T, Patsopoulos NA, Weiser M (2014) Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD005041.pub2","DOI":"10.1002\/14651858.CD005041.pub2"},{"issue":"12","key":"330_CR45","first-page":"678","volume":"34","author":"SV Faraone","year":"2009","unstructured":"Faraone SV (2009) Using meta-analysis to compare the efficacy of medications for attention-deficit\/hyperactivity disorder in youths. P T 34(12):678\u2013694","journal-title":"P T"},{"key":"330_CR46","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.neubiorev.2018.02.001","volume":"87","author":"SV Faraone","year":"2018","unstructured":"Faraone SV (2018) The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit\/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev 87:255\u2013270. https:\/\/doi.org\/10.1016\/j.neubiorev.2018.02.001","journal-title":"Neurosci Biobehav Rev"},{"issue":"4","key":"330_CR47","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00787-009-0054-3","volume":"19","author":"SV Faraone","year":"2010","unstructured":"Faraone SV, Buitelaar J (2010) Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 19(4):353\u2013364. https:\/\/doi.org\/10.1007\/s00787-009-0054-3","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"1","key":"330_CR48","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jaac.2019.06.012","volume":"59","author":"SV Faraone","year":"2020","unstructured":"Faraone SV, Rostain AL, Montano CB, Mason O, Antshel KM, Newcorn JH (2020) Systematic review: nonmedical use of prescription stimulants: risk factors, outcomes, and risk reduction strategies. J Am Acad Child Adolesc Psychiatry 59(1):100\u2013112. https:\/\/doi.org\/10.1016\/j.jaac.2019.06.012","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"330_CR49","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/CRD.0000000000000234","volume":"27","author":"TB Fay","year":"2019","unstructured":"Fay TB, Alpert MA (2019) Cardiovascular effects of drugs used to treat attention-deficit\/hyperactivity disorder part 2 impact on cardiovascular events and recommendations for evaluation and monitoring. Cardiol Rev 27(4):173\u2013178. https:\/\/doi.org\/10.1097\/CRD.0000000000000234","journal-title":"Cardiol Rev"},{"issue":"3","key":"330_CR50","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4102\/sajpsychiatry.v19i3.943","volume":"19","author":"AJ Flisher","year":"2013","unstructured":"Flisher AJ, Hawkridge S (2013) Attention deficit hyperactivity disorder in children and adolescents. S Afr J Psychiatry 19(3):5. https:\/\/doi.org\/10.4102\/sajpsychiatry.v19i3.943","journal-title":"S Afr J Psychiatry"},{"issue":"3","key":"330_CR51","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s12402-014-0144-z","volume":"6","author":"J Geissler","year":"2014","unstructured":"Geissler J, Romanos M, Hegerl U, Hensch T (2014) Hyperactivity and sensation seeking as autoregulatory attempts to stabilize brain arousal in ADHD and mania? Atten Defic Hyperact Disord 6(3):159\u2013173. https:\/\/doi.org\/10.1007\/s12402-014-0144-z","journal-title":"Atten Defic Hyperact Disord"},{"issue":"5","key":"330_CR52","first-page":"273","volume":"35","author":"DW Goodman","year":"2010","unstructured":"Goodman DW (2010) Lisdexamfetamine dimesylate (Vyvanse), a prodrug stimulant for attention-deficit\/hyperactivity disorder. P T 35(5):273\u2013287","journal-title":"P T"},{"issue":"7","key":"330_CR53","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.biopsych.2009.09.029","volume":"67","author":"MJ Groom","year":"2010","unstructured":"Groom MJ, Scerif G, Liddle PF, Batty MJ, Liddle EB, Roberts KL, Cahill JD, Liotti M, Hollis C (2010) Effects of motivation and medication on electrophysiological markers of response inhibition in children with attention-deficit\/hyperactivity disorder. Biol Psychiatry 67(7):624\u2013631. https:\/\/doi.org\/10.1016\/j.biopsych.2009.09.029","journal-title":"Biol Psychiatry"},{"issue":"10","key":"330_CR54","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.euroneuro.2011.08.008","volume":"21","author":"A Gustavsson","year":"2011","unstructured":"Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M, Faravelli C, Fratiglioni L, Gannon B, Jones DH, Jennum P, Jordanova A, J\u00f6nsson L, Karampampa K, Knapp M, Kobelt G, Kurth T, Lieb R, Linde M, Ljungcrantz C, Maercker A, Melin B, Moscarelli M, Musayev A, Norwood F, Preisig M, Pugliatti M, Rehm J, Salvador-Carulla L, Schlehofer B, Simon R, Steinhausen H-C, Stovner LJ, Vallat J-M, den Bergh PV, van Os J, Vos P, Xu W, Wittchen H-U, J\u00f6nsson B, Olesen J (2011) Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21(10):718\u2013779. https:\/\/doi.org\/10.1016\/j.euroneuro.2011.08.008","journal-title":"Eur Neuropsychopharmacol"},{"issue":"10","key":"330_CR55","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hbm.21127","volume":"32","author":"T Hahn","year":"2011","unstructured":"Hahn T, Heinzel S, Dresler T, Plichta MM, Renner TJ, Markulin F, Jakob PM, Lesch KP, Fallgatter AJ (2011) Association between reward-related activation in the ventral striatum and trait reward sensitivity is moderated by dopamine transporter genotype. Hum Brain Mapp 32(10):1557\u20131565. https:\/\/doi.org\/10.1002\/hbm.21127","journal-title":"Hum Brain Mapp"},{"issue":"9","key":"330_CR56","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.biopsych.2010.06.017","volume":"68","author":"J Hannestad","year":"2010","unstructured":"Hannestad J, Gallezot J-D, Planeta-Wilson B, Lin S-F, Williams WA, van Dyck CH, Malison RT, Carson RE, Ding Y-S (2010) Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo. Biol Psychiatry 68(9):854\u2013860. https:\/\/doi.org\/10.1016\/j.biopsych.2010.06.017","journal-title":"Biol Psychiatry"},{"issue":"12","key":"330_CR57","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1111\/jcpp.12917","volume":"59","author":"LW Hawk","year":"2018","unstructured":"Hawk LW, Fosco WD, Colder CR, Waxmonsky JG, Pelham WE, Rosch KS (2018) How do stimulant treatments for ADHD work? Evidence for mediation by improved cognition. J Child Psychol Psychiatry 59(12):1271\u20131281. https:\/\/doi.org\/10.1111\/jcpp.12917","journal-title":"J Child Psychol Psychiatry"},{"issue":"6","key":"330_CR58","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1177\/0269881113482532","volume":"27","author":"DJ Heal","year":"2013","unstructured":"Heal DJ, Smith SL, Gosden J, Nutt DJ (2013) Amphetamine, past and present \u2013 a pharmacological and clinical perspective. J Psychopharmacol 27(6):479\u2013496. https:\/\/doi.org\/10.1177\/0269881113482532","journal-title":"J Psychopharmacol"},{"issue":"3","key":"330_CR59","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40263-017-0410-7","volume":"31","author":"L Hennissen","year":"2017","unstructured":"Hennissen L, Bakker MJ, Banaschewski T, Carucci S, Coghill D, Danckaerts M, Dittmann RW, Hollis C, Kovshoff H, McCarthy S, Nagy P, Sonuga-Barke E, Wong ICK, Zuddas A, Rosenthal E, Buitelaar JK (2017) Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: a systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine. CNS Drugs 31(3):199\u2013215. https:\/\/doi.org\/10.1007\/s40263-017-0410-7","journal-title":"CNS Drugs"},{"issue":"2","key":"330_CR60","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jaac.2013.11.009","volume":"53","author":"T Hirota","year":"2014","unstructured":"Hirota T (2014) Alpha-2 agonists for attention-deficit\/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. Adolesc Psychiatry 53(2):21","journal-title":"Adolesc Psychiatry"},{"issue":"9","key":"330_CR61","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00787-012-0286-5","volume":"21","author":"P Hodgkins","year":"2012","unstructured":"Hodgkins P, Shaw M, Coghill D, Hechtman L (2012) Amfetamine and methylphenidate medications for attention-deficit\/hyperactivity disorder: complementary treatment options. Eur Child Adolesc Psychiatry 21(9):477\u2013492. https:\/\/doi.org\/10.1007\/s00787-012-0286-5","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"1","key":"330_CR62","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40263-019-00686-4","volume":"34","author":"R Houghton","year":"2020","unstructured":"Houghton R, de Vries F, Loss G (2020) Psychostimulants\/atomoxetine and serious cardiovascular events in children with ADHD or autism spectrum disorder. CNS Drugs 34(1):93\u2013101. https:\/\/doi.org\/10.1007\/s40263-019-00686-4","journal-title":"CNS Drugs"},{"key":"330_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40261-015-0336-0","volume":"36","author":"M Huss","year":"2016","unstructured":"Huss M, Chen W, Ludolph AG (2016) Guanfacine extended release: a new pharmacological treatment option in Europe. Clin Drug Investig 36:1\u201325. https:\/\/doi.org\/10.1007\/s40261-015-0336-0","journal-title":"Clin Drug Investig"},{"key":"330_CR64","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.2147\/NDT.S130444","volume":"13","author":"M Huss","year":"2017","unstructured":"Huss M, Duhan P, Gandhi P, Chen C-W, Spannhuth C, Kumar V (2017) Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity. Neuropsychiatr Dis Treat 13:1741\u20131751. https:\/\/doi.org\/10.2147\/NDT.S130444","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"5","key":"330_CR65","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1177\/2045125316647686","volume":"6","author":"SL Hutchison","year":"2016","unstructured":"Hutchison SL, Ghuman JK, Ghuman HS, Karpov I, Schuster JM (2016) Efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in patients with common comorbidities in children, adolescents and adults: a review. Ther Adv Psychopharm 6(5):317\u2013334. https:\/\/doi.org\/10.1177\/2045125316647686","journal-title":"Ther Adv Psychopharm"},{"issue":"1","key":"330_CR66","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12402-014-0142-1","volume":"7","author":"CM Jensen","year":"2015","unstructured":"Jensen CM, Steinhausen H-C (2015) Comorbid mental disorders in children and adolescents with attention-deficit\/hyperactivity disorder in a large nationwide study. Atten Defic Hyperact Disord 7(1):27\u201338. https:\/\/doi.org\/10.1007\/s12402-014-0142-1","journal-title":"Atten Defic Hyperact Disord"},{"issue":"9","key":"330_CR67","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1176\/appi.ajp.162.9.1628","volume":"162","author":"PS Jensen","year":"2005","unstructured":"Jensen PS, Garcia JA, Glied S, Crowe M, Foster M, Schlander M, Hinshaw S, Vitiello B, Arnold LE, Elliott G, Hechtman L, Newcorn JH, Pelham WE, Swanson J, Wells K (2005) Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD. Am J Psychiatry 162(9):1628\u20131636","journal-title":"Am J Psychiatry"},{"issue":"8","key":"330_CR68","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00787-017-0962-6","volume":"26","author":"A Joseph","year":"2017","unstructured":"Joseph A, Ayyagari R, Xie M, Cai S, Xie J, Huss M, Sikirica V (2017) Comparative efficacy and safety of attention-deficit\/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison. Eur Child Adolesc Psych 26(8):875\u2013897. https:\/\/doi.org\/10.1007\/s00787-017-0962-6","journal-title":"Eur Child Adolesc Psych"},{"issue":"3","key":"330_CR69","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.biopsych.2004.11.009","volume":"57","author":"A Jucaite","year":"2005","unstructured":"Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L (2005) Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit\/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. Biol Psychiatry 57(3):229\u2013238. https:\/\/doi.org\/10.1016\/j.biopsych.2004.11.009","journal-title":"Biol Psychiatry"},{"issue":"6","key":"330_CR70","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/jcpp.12217","volume":"55","author":"SL Karalunas","year":"2014","unstructured":"Karalunas SL, Geurts HM, Konrad K, Bender S, Nigg JT (2014) Annual research review: reaction time variability in ADHD and autism spectrum disorders: measurement and mechanisms of a proposed trans-diagnostic phenotype. J Child Psychol Psychiatry 55(6):685\u2013710. https:\/\/doi.org\/10.1111\/jcpp.12217","journal-title":"J Child Psychol Psychiatry"},{"issue":"6","key":"330_CR71","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1002\/hbm.21058","volume":"31","author":"K Konrad","year":"2010","unstructured":"Konrad K, Eickhoff SB (2010) Is the ADHD brain wired differently? A review on structural and functional connectivity in attention deficit hyperactivity disorder. Hum Brain Mapp 31(6):904\u2013916. https:\/\/doi.org\/10.1002\/hbm.21058","journal-title":"Hum Brain Mapp"},{"key":"330_CR72","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.neubiorev.2019.09.023","volume":"107","author":"H Krinzinger","year":"2019","unstructured":"Krinzinger H, Hall CL, Groom MJ, Ansari MT, Banaschewski T, Buitelaar JK, Carucci S, Coghill D, Danckaerts M, Dittmann RW, Falissard B, Garas P, Inglis SK, Kovshoff H, Kochhar P, McCarthy S, Nagy P, Neubert A, Roberts S, Sayal K, Sonuga-Barke E, Wong ICK, Xia J, Zuddas A, Hollis C, Konrad K, Liddle EB (2019) Neurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: a map of the current evidence. Neurosci Biobehav Rev 107:945\u2013968. https:\/\/doi.org\/10.1016\/j.neubiorev.2019.09.023","journal-title":"Neurosci Biobehav Rev"},{"key":"330_CR73","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/7854_2011_145","volume":"9","author":"J Kuntsi","year":"2012","unstructured":"Kuntsi J, Klein C (2012) Intraindividual variability in ADHD and its implications for research of causal links. Curr Top Behav Neurosci 9:67\u201391. https:\/\/doi.org\/10.1007\/7854_2011_145","journal-title":"Curr Top Behav Neurosci"},{"issue":"7","key":"330_CR74","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/j.1469-7610.2010.02333.x","volume":"52","author":"EB Liddle","year":"2011","unstructured":"Liddle EB, Hollis C, Batty MJ, Groom MJ, Totman JJ, Liotti M, Scerif G, Liddle PF (2011) Task-related default mode network modulation and inhibitory control in ADHD: effects of motivation and methylphenidate. J Child Psychol Psychiatry 52(7):761\u2013771. https:\/\/doi.org\/10.1111\/j.1469-7610.2010.02333.x","journal-title":"J Child Psychol Psychiatry"},{"issue":"10","key":"330_CR75","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s00787-018-1217-x","volume":"28","author":"H Liu","year":"2019","unstructured":"Liu H, Feng W, Zhang D (2019) Association of ADHD medications with the risk of cardiovascular diseases: a meta-analysis. Eur Child Adolesc Psych 28(10):1283\u20131293. https:\/\/doi.org\/10.1007\/s00787-018-1217-x","journal-title":"Eur Child Adolesc Psych"},{"issue":"3","key":"330_CR76","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1097\/JCP.0b013e3181733560","volume":"28","author":"JS Markowitz","year":"2008","unstructured":"Markowitz JS, Patrick KS (2008) Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? J Clin Psychopharmacol 28(3):S54. https:\/\/doi.org\/10.1097\/JCP.0b013e3181733560","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"330_CR77","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41598-020-57595-6","volume":"10","author":"E Martinez","year":"2020","unstructured":"Martinez E, Pasquereau B, Drui G, Saga Y, M\u00e9t\u00e9reau \u00c9, Tremblay L (2020) Ventral striatum supports methylphenidate therapeutic effects on impulsive choices expressed in temporal discounting task. Sci Rep 10(1):716. https:\/\/doi.org\/10.1038\/s41598-020-57595-6","journal-title":"Sci Rep"},{"issue":"3","key":"330_CR78","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/2042098616679636","volume":"8","author":"J Martinez-Raga","year":"2017","unstructured":"Martinez-Raga J, Ferreros A, Knecht C, de Alvaro R, Carabal E (2017) Attention-deficit hyperactivity disorder medication use: factors involved in prescribing, safety aspects and outcomes. Ther Adv Drug Saf 8(3):87\u201399. https:\/\/doi.org\/10.1177\/2042098616679636","journal-title":"Ther Adv Drug Saf"},{"issue":"4","key":"330_CR79","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/ddrr.35","volume":"14","author":"JD McQuade","year":"2008","unstructured":"McQuade JD, Hoza B (2008) Peer problems in attention deficit hyperactivity disorder: current status and future directions. Dev Disabil Res Revs 14(4):320\u2013324. https:\/\/doi.org\/10.1002\/ddrr.35","journal-title":"Dev Disabil Res Revs"},{"issue":"7","key":"330_CR80","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1097\/01.chi.0000125089.35109.81","volume":"43","author":"D Michelson","year":"2004","unstructured":"Michelson D, Buitelaar JK, Danckaerts M, Gillberg C, Spencer TJ, Zuddas A, Faries DE, Zhang S, Biederman J (2004) Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 43(7):896\u2013904. https:\/\/doi.org\/10.1097\/01.chi.0000125089.35109.81","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"330_CR81","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1146\/annurev.neuro.24.1.167","volume":"24","author":"EK Miller","year":"2001","unstructured":"Miller EK, Cohen JD (2001) An integrative theory of prefrontal cortex function. Annu Rev Neurosci 24(1):167\u2013202. https:\/\/doi.org\/10.1146\/annurev.neuro.24.1.167","journal-title":"Annu Rev Neurosci"},{"issue":"1","key":"330_CR82","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1087054714559643","volume":"21","author":"CR Moreira Maia","year":"2017","unstructured":"Moreira Maia CR, Cortese S, Caye A, Deakin TK, Polanczyk GV, Polanczyk CA, Paim Rohde LA (2017) Long-term efficacy of methylphenidate immediate-release for the treatment of childhood ADHD: a systematic review and meta-analysis. J Atten Disord 21(1):3\u201313. https:\/\/doi.org\/10.1177\/1087054714559643","journal-title":"J Atten Disord"},{"key":"330_CR83","unstructured":"National Institute of Health and Care Excellence (2018) Overview | Attention deficit hyperactivity disorder: diagnosis and management | Guidance | NICE. https:\/\/www.nice.org.uk\/guidance\/ng87. Accessed 9 Jul 2021"},{"issue":"5","key":"330_CR84","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1177\/0269881116632377","volume":"30","author":"H-C Ni","year":"2016","unstructured":"Ni H-C, Gu S-LH, Lin H-Y, Lin Y-J, Yang L-K, Huang H-C, Gau SS-F (2016) Atomoxetine could improve intra-individual variability in drug-naive adults with attention-deficit\/hyperactivity disorder comparably with methylphenidate: a head-to-head randomized clinical trial. J Psychopharmacol 30(5):459\u2013467. https:\/\/doi.org\/10.1177\/0269881116632377","journal-title":"J Psychopharmacol"},{"issue":"4","key":"330_CR85","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.cpr.2007.10.003","volume":"28","author":"JS Nijmeijer","year":"2008","unstructured":"Nijmeijer JS, Minderaa RB, Buitelaar JK, Mulligan A, Hartman CA, Hoekstra PJ (2008) Attention-deficit\/hyperactivity disorder and social dysfunctioning. Clin Psychol Rev 28(4):692\u2013708. https:\/\/doi.org\/10.1016\/j.cpr.2007.10.003","journal-title":"Clin Psychol Rev"},{"key":"330_CR86","doi-asserted-by":"publisher","unstructured":"Osland ST, Steeves TDL, Pringsheim T (2018) Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev (6):CD007990. https:\/\/doi.org\/10.1002\/14651858.CD007990.pub3","DOI":"10.1002\/14651858.CD007990.pub3"},{"issue":"6","key":"330_CR87","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.neubiorev.2011.02.015","volume":"35","author":"NNJ Rommelse","year":"2011","unstructured":"Rommelse NNJ, Geurts HM, Franke B, Buitelaar JK, Hartman CA (2011) A review on cognitive and brain endophenotypes that may be common in autism spectrum disorder and attention-deficit\/hyperactivity disorder and facilitate the search for pleiotropic genes. Neurosci Biobehav Rev 35(6):1363\u20131396. https:\/\/doi.org\/10.1016\/j.neubiorev.2011.02.015","journal-title":"Neurosci Biobehav Rev"},{"key":"330_CR88","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3389\/fnhum.2018.00100","volume":"12","author":"K Rubia","year":"2018","unstructured":"Rubia K (2018) Cognitive neuroscience of attention deficit hyperactivity disorder (ADHD) and its clinical translation. Front Hum Neurosci 12:100. https:\/\/doi.org\/10.3389\/fnhum.2018.00100","journal-title":"Front Hum Neurosci"},{"issue":"8","key":"330_CR89","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.biopsych.2013.10.016","volume":"76","author":"K Rubia","year":"2014","unstructured":"Rubia K, Alegria AA, Cubillo AI, Smith AB, Brammer MJ, Radua J (2014) Effects of stimulants on brain function in attention-deficit\/hyperactivity disorder: a systematic review and meta-analysis. Biol Psychiatry 76(8):616\u2013628. https:\/\/doi.org\/10.1016\/j.biopsych.2013.10.016","journal-title":"Biol Psychiatry"},{"key":"330_CR90","doi-asserted-by":"publisher","first-page":"a1060","DOI":"10.4102\/sajpsychiatry.v23i0.1060","volume":"23","author":"R Schoeman","year":"2017","unstructured":"Schoeman R, Liebenberg R (2017) The south African Society of Psychiatrists\/Psychiatry Management Group management guidelines for adult attention-deficit\/hyperactivity disorder. S Afr J Psychiatr 23:a1060. https:\/\/doi.org\/10.4102\/sajpsychiatry.v23i0.1060","journal-title":"S Afr J Psychiatr"},{"issue":"1","key":"330_CR91","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1177\/1087054720961828","volume":"26","author":"E Sciberras","year":"2020","unstructured":"Sciberras E, Streatfeild J, Ceccato T, Pezzullo L, Scott JG, Middeldorp CM, Hutchins P, Paterson R, Bellgrove MA, Coghill D (2020) Social and economic costs of attention-deficit\/hyperactivity disorder across the lifespan. J Atten Disord 26(1):72\u201387. https:\/\/doi.org\/10.1177\/1087054720961828","journal-title":"J Atten Disord"},{"issue":"Suppl 2","key":"330_CR92","doi-asserted-by":"publisher","first-page":"176","DOI":"10.4103\/psychiatry.IndianJPsychiatry_543_18","volume":"61","author":"R Shah","year":"2019","unstructured":"Shah R, Grover S, Avasthi A (2019) Clinical practice guidelines for the assessment and management of attention-deficit\/hyperactivity disorder. Indian J Psychiatry 61(Suppl 2):176\u2013193. https:\/\/doi.org\/10.4103\/psychiatry.IndianJPsychiatry_543_18","journal-title":"Indian J Psychiatry"},{"issue":"3","key":"330_CR93","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/hbm.23071","volume":"37","author":"HL Sigurdardottir","year":"2016","unstructured":"Sigurdardottir HL, Kranz GS, Rami-Mark C, James GM, Vanicek T, Gryglewski G, Kautzky A, Hienert M, Traub-Weidinger T, Mitterhauser M, Wadsak W, Hacker M, Rujescu D, Kasper S, Lanzenberger R (2016) Effects of norepinephrine transporter gene variants on NET binding in ADHD and healthy controls investigated by PET. Hum Brain Mapp 37(3):884\u2013895. https:\/\/doi.org\/10.1002\/hbm.23071","journal-title":"Hum Brain Mapp"},{"issue":"4","key":"330_CR94","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/00004583-199604000-00008","volume":"35","author":"T Spencer","year":"1996","unstructured":"Spencer T, Biederman J, Wilens T, Harding M, O\u2019Donnell D, Griffin S (1996) Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 35(4):409\u2013432. https:\/\/doi.org\/10.1097\/00004583-199604000-00008","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"11","key":"330_CR95","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.biopsych.2014.09.013","volume":"77","author":"RC Spencer","year":"2015","unstructured":"Spencer RC, Devilbiss DM, Berridge CW (2015) The cognition-enhancing effects of psychostimulants involve direct action in the prefrontal cortex. Biol Psychiatry 77(11):940\u2013950. https:\/\/doi.org\/10.1016\/j.biopsych.2014.09.013","journal-title":"Biol Psychiatry"},{"key":"330_CR96","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.psychres.2017.12.043","volume":"261","author":"M Strau\u00df","year":"2018","unstructured":"Strau\u00df M, Ulke C, Paucke M, Huang J, Mauche N, Sander C, Stark T, Hegerl U (2018) Brain arousal regulation in adults with attention-deficit\/hyperactivity disorder (ADHD). Psychiatry Res 261:102\u2013108. https:\/\/doi.org\/10.1016\/j.psychres.2017.12.043","journal-title":"Psychiatry Res"},{"issue":"1\u20132","key":"330_CR97","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0166-4328(01)00433-8","volume":"130","author":"JM Swanson","year":"2002","unstructured":"Swanson JM, Volkow ND (2002) Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD. Behav Brain Res 130(1\u20132):73\u201378","journal-title":"Behav Brain Res"},{"issue":"1","key":"330_CR98","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/npp.2010.160","volume":"36","author":"J Swanson","year":"2011","unstructured":"Swanson J, Baler RD, Volkow ND (2011) Understanding the effects of stimulant medications on cognition in individuals with attention-deficit hyperactivity disorder: a decade of progress. Neuropsychopharmacology 36(1):207\u2013226. https:\/\/doi.org\/10.1038\/npp.2010.160","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"330_CR99","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1097\/01.chi.0000093323.86599.44","volume":"42","author":"AR Swensen","year":"2003","unstructured":"Swensen AR, Birnbaum HG, Secnik K, Marynchenko M, Greenberg P, Claxton A (2003) Attention-deficit\/hyperactivity disorder: increased costs for patients and their families. J Am Acad Child Adolesc Psychiatry 42(12):1415\u20131423. https:\/\/doi.org\/10.1097\/01.chi.0000093323.86599.44","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"330_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-019-0619-y","volume":"9","author":"C Ulke","year":"2019","unstructured":"Ulke C, Rullmann M, Huang J, Luthardt J, Becker G-A, Patt M, Meyer PM, Tiepolt S, Hesse S, Sabri O, Strau\u00df M (2019) Adult attention-deficit\/hyperactivity disorder is associated with reduced norepinephrine transporter availability in right attention networks: a (S,S)-O-[11 C]methylreboxetine positron emission tomography study. Transl Psychiatry 9(1):1\u201310. https:\/\/doi.org\/10.1038\/s41398-019-0619-y","journal-title":"Transl Psychiatry"},{"issue":"12","key":"330_CR101","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1001\/jamapsychiatry.2014.1226","volume":"71","author":"T Vanicek","year":"2014","unstructured":"Vanicek T, Spies M, Rami-Mark C, Savli M, H\u00f6flich A, Kranz GS, Hahn A, Kutzelnigg A, Traub-Weidinger T, Mitterhauser M, Wadsak W, Hacker M, Volkow ND, Kasper S, Lanzenberger R (2014) The norepinephrine transporter in attention-deficit\/hyperactivity disorder investigated with positron emission tomography. JAMA Psychiat 71(12):1340\u20131349. https:\/\/doi.org\/10.1001\/jamapsychiatry.2014.1226","journal-title":"JAMA Psychiat"},{"issue":"10","key":"330_CR102","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1176\/ajp.155.10.1325","volume":"155","author":"ND Volkow","year":"1998","unstructured":"Volkow ND, Gene-J W, Fowler JS, Gatley SJ, Logan J, Ding Y-S, Hitzemann R, Pappas N (1998) Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 155(10):1325\u20131331. https:\/\/doi.org\/10.1176\/ajp.155.10.1325","journal-title":"Am J Psychiatry"},{"issue":"6","key":"330_CR103","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S0924-977X(02)00104-9","volume":"12","author":"ND Volkow","year":"2002","unstructured":"Volkow ND, Fowler JS, Wang GJ, Ding YS, Gatley SJ (2002a) Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies. Eur Neuropsychopharmacol 12(6):557\u2013566","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"330_CR104","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/syn.10038","volume":"43","author":"ND Volkow","year":"2002","unstructured":"Volkow ND, Wang G-J, Fowler JS, Logan J, Franceschi D, Maynard L, Ding Y-S, Gatley SJ, Gifford A, Zhu W, Swanson JM (2002b) Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse 43(3):181\u2013187. https:\/\/doi.org\/10.1002\/syn.10038","journal-title":"Synapse"},{"issue":"2","key":"330_CR105","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2007.03.015","volume":"129","author":"M Wang","year":"2007","unstructured":"Wang M, Ramos BP, Paspalas CD, Shu Y, Simen A, Duque A, Vijayraghavan S, Brennan A, Dudley A, Nou E, Mazer JA, McCormick DA, Arnsten AFT (2007) Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell 129(2):397\u2013410. https:\/\/doi.org\/10.1016\/j.cell.2007.03.015","journal-title":"Cell"},{"key":"330_CR106","doi-asserted-by":"publisher","unstructured":"Wolraich ML, Hagan JF, Allan C, Chan E, Davison D, Earls M, Evans SW, Flinn SK, Froehlich T, Frost J, Holbrook JR, Lehmann CU, Lessin HR, Okechukwu K, Pierce KL, Winner JD, Zurhellen W (2019) Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit\/hyperactivity disorder in children and adolescents. Pediatrics 144(4). https:\/\/doi.org\/https:\/\/doi.org\/10.1542\/peds.2019-2528","DOI":"10.1542\/peds.2019-2528"},{"key":"330_CR107","unstructured":"World Health Organisation The World Health Organization Quality of Life (WHOQOL) (2021). https:\/\/www.who.int\/publications-detail-redierct\/WHO-HIS-HSI-Rev.2012.03. Accessed 24 May 2021"},{"issue":"7","key":"330_CR108","doi-asserted-by":"publisher","first-page":"581","DOI":"10.2165\/11633900-000000000-00000","volume":"26","author":"EQ Wu","year":"2012","unstructured":"Wu EQ, Hodgkins P, Ben-Hamadi R, Setyawan J, Xie J, Sikirica V, Du EX, Yan SY, Erder MH (2012) Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review. CNS Drugs 26(7):581\u2013600. https:\/\/doi.org\/10.2165\/11633900-000000000-00000","journal-title":"CNS Drugs"}],"container-title":["Current Topics in Behavioral Neurosciences","New Discoveries in the Behavioral Neuroscience of Attention-Deficit Hyperactivity Disorder"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/7854_2022_330","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T22:07:37Z","timestamp":1659564457000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/7854_2022_330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9783031118012","9783031118029"],"references-count":108,"URL":"https:\/\/doi.org\/10.1007\/7854_2022_330","relation":{},"ISSN":["1866-3370","1866-3389"],"issn-type":[{"value":"1866-3370","type":"print"},{"value":"1866-3389","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"30 April 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}